Get startedLog in
    Picture of Filana Therapeutics logo

    FLNA — Filana Therapeutics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMicro CapNeutral
    All News

    Brief: Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’s Disease

    Picture of Filana Therapeutics logoFilana Therapeutics
    06/11/2023 14:27
    Nov 6 (Reuters) - Cassava Sciences Inc  SAVA.O :
    * CASSAVA SCIENCES COMPLETES ENROLLMENT FOR PIVOTAL PHASE 3
PROGRAM OF SIMUFILAM IN ALZHEIMER’S DISEASE
    * CASSAVA SCIENCES INC- TOP-LINE RESULTS FOR ON-GOING,
52-WEEK
PHASE 3 TRIAL EXPECTED APPROXIMATELY YEAR-END 2024
    * CASSAVA SCIENCES INC- TOP-LINE RESULTS FOR ON-GOING,
76-WEEK
PHASE 3 TRIAL EXPECTED APPROXIMATELY MID-YEAR 2025

Source text for Eikon:  ID:nGNX1CmtRF 
Further company coverage:  SAVA.O 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Filana Therapeutics

    See all news